Rosetta Biosoftware Licenses the Rosetta Resolver Gene Expression Analysis System to FoxHollow Technologies
Rosetta Biosoftware announced today that FoxHollow Technologies has licensed the Rosetta Resolver(R) system for research on cardiovascular disease. FoxHollow Technologies developed and markets the SilverHawk(TM) Plaque Excision System, an atherosclerotic plaque excision device approved in the U.S. for the treatment of peripheral arterial disease (PAD). The Biologicals Division at FoxHollow will use the Resolver application to correlate genetic profiles of human atherosclerotic plaque samples with clinical findings as a tool for the development and evaluation of therapies targeted at atherosclerosis.
“The flexibility of the Rosetta Resolver system to identify predicative biomarkers for a variety of cardiovascular diseases will provide FoxHollow Technologies with a reliable framework for their gene expression research,” said Yelena Shevelenko, vice president and general manager of Rosetta Biosoftware. “Its comprehensive set of data analysis tools and advanced data management capabilities make it the optimum tool for the analysis of large amounts of gene expression data in conjunction with clinical data in a collaborative environment.”
The Rosetta Resolver system will be used by the Biologicals Division at FoxHollow Technologies to evaluate data generated by the novel, large-scale pharmacogenomics collaboration between FoxHollow and Merck & Co., Inc. This collaboration was formed in September 2005 to identify new biomarkers for use in cardiovascular drug development. As part of this unique collaboration, genetic profiles are generated from atherosclerotic plaque samples removed from patients with cardiovascular disease using FoxHollow Technologies’ minimally invasive SilverHawk(TM) Plaque Excision System.
“We are committed to treating PAD with innovative biological and mechanical technologies,” said Daniel J. Lerner, M.D., vice president of Molecular Programs at FoxHollow Technologies. “By partnering the Resolver system with the gene expression and clinical data generated from our collaboration with Merck, we will be able to explore the molecular basis of atherosclerosis in a completely novel manner, enabling us to develop and evaluate innovative treatments for patients with PAD.”
The Rosetta Resolver system is developed and supported by Rosetta Biosoftware, and is distributed exclusively by Agilent Technologies.
About FoxHollow Technologies
FoxHollow Technologies, Inc. develops and markets minimally invasive plaque excision devices for the treatment of peripheral artery disease (PAD). An estimated 12 million people in the U.S. are thought to suffer from PAD, with 2.5 million patients currently diagnosed. PAD results from plaque that accumulates in the arteries and blocks blood flow in the legs. These blockages can result in severe pain for patients and very limited physical mobility. The company’s SilverHawk System is a minimally invasive method of removing the obstructive plaque and restoring blood flow to the legs and feet. For more information, please visit the company’s website at www.foxhollowtech.com .
About the Rosetta Resolver System
The Rosetta Resolver system is a high-capacity data storage, retrieval, and analysis solution for gene expression data. The system is ideal for life science research organizations that need to assess compound specificity or toxicity, identify new genes or therapeutic targets or compare and analyze large databases of expression profiles. The Rosetta Resolver system combines flexibility and ease of use with high-performance algorithms to produce a comprehensive solution for rapid analysis of gene expression data. The Rosetta Resolver system can accept and analyze data from a wide variety of expression profiling formats, including Agilent DNA microarrays, and applies Rosetta Biosoftware’s proprietary error models to yield quality statistics for every gene expression measurement within the system. These statistics are automatically leveraged by Rosetta Resolver system analysis tools for optimal results.
In addition to FoxHollow Technologies, life science research organizations that have licensed the Rosetta Resolver system include many of the top pharmaceutical companies in the world, such as Aventis Pharmaceuticals, Bristol-Myers Squibb, GlaxoSmithKline and Merck & Co., Inc., as well as premier academic institutions such as the Harvard University Center for Genomics Research and the California Institute of Technology. Additional information about the Rosetta Resolver system can be found on the Rosetta Biosoftware Web site at www.rosettabio.com .
About Rosetta Biosoftware
Rosetta Biosoftware is a leading provider of informatics solutions for life science research. Its enterprise software solutions, including the Rosetta Resolver and Rosetta Elucidator systems, empower life scientists with advanced, scalable, and easy-to-use analysis platforms that accelerate discovery research. Rosetta Biosoftware is a business unit of Rosetta Inpharmatics LLC, a wholly owned subsidiary of Merck & Co., Inc. (NYSE: MRK). More information about Rosetta Biosoftware is available at www.rosettabio.com .
Rosetta Resolver and Elucidator are registered trademarks of Rosetta Inpharmatics LLC.
